ST宁科实际控制人及一致行动人增持股份计划公告详解
一、公告要点梳理
- 增持主体：公司实际控制人刘喜荣先生及其一致行动人湖南醇投实业发展有限公司（湖南醇投）。在本次增持计划实施前，两者均未直接持有公司股份。
- 增持计划：两位主体计划自公告披露之日起6个月内，通过上海证券交易所集中竞价交易方式，合计增持金额为不低于人民币3,000万元（含交易费用），不超过人民币6,000万元（含交易费用）。具体增持价格不设定区间，将根据二级市场情况择机实施。
- 增持时间窗口：2026年7月28日至2027年1月27日。
- 资金来源：自有及自筹资金。
- 承诺：增持实施期间及法定期限内不减持所持公司股份。
- 控股结构：刘喜荣先生为宁夏中科生物科技股份有限公司的实际控制人，一致行动人湖南醇投为其控制企业。此外，刘喜荣还是湖南新合新生物医药有限公司的实际控制人，三者形成一致行动关系，目前湖南新合新生物医药有限公司持有公司22.10%的股份。
二、对股东与投资者的影响及需重点关注事项
- 股东信号：实际控制人及其一致行动人主动增持公司股份，彰显对公司未来持续稳定发展的信心和对公司长期投资价值的认可，有助于提振市场投资者信心，维护资本市场稳定。
- 价格敏感信息：大股东增持往往会被市场解读为公司基本面良好、管理层对未来增长有信心，短期内可能对公司股价形成支撑甚至提振作用。
- 风险提示：公司提示本次增持计划可能因政策、资本市场情况变化或其他不可预见因素导致计划延迟实施或无法实施，投资者需关注相关风险披露。
- 股权结构变化：本次增持不会导致公司控股股东及实际控制人发生变化，股权结构整体稳定。
- 信息披露：公司承诺将持续关注增持计划进展，并及时履行信息披露义务。
三、详细信息
- 刘喜荣及湖南醇投目前持股：增持前均未直接持有公司股份，但通过湖南新合新生物医药有限公司间接控制22.10%股份。
- 增持金额区间：3,000万元-6,000万元，未设定具体股份数量及增持比例区间。
- 实施方式：通过上海证券交易所集中竞价交易完成。
- 承诺合规：增持严格遵守《证券法》《上市公司收购管理办法》《上海证券交易所股票上市规则》等相关法规。
四、投资者建议
本次增持计划释放出大股东看好公司前景的积极信号，短期内可能对股价形成正面影响。建议投资者关注公司后续增持进展及市场反馈，同时警惕政策及市场环境变化可能带来的不确定性。
免责声明：本文仅为财经新闻资讯，不构成任何投资建议。投资有风险，入市需谨慎。请投资者结合自身实际情况进行独立判断。
English Version
ST Ningke: Details on Controlling Shareholder and Acting-in-Concert Party’s Share Purchase Plan
1. Key Points of the Announcement
- Buyers: The company’s actual controller, Mr. Liu Xirong, and his acting-in-concert party, Hunan Chuntou Industrial Development Co., Ltd. (Hunan Chuntou). Before this plan, neither held shares directly in the company.
- Purchase Plan: Both parties plan to purchase, via centralized bidding on the Shanghai Stock Exchange, a combined amount of not less than RMB 30 million and not more than RMB 60 million (including transaction fees) within 6 months from the announcement. No fixed price range; purchases will be made according to market conditions.
- Purchase Window: From July 28, 2026, to January 27, 2027.
- Funding Source: Self-owned or self-raised funds.
- Commitment: No reduction of holdings during the purchase period and statutory period.
- Shareholding Structure: Mr. Liu is the actual controller of the company and both Hunan Chuntou and Hunan Xinhexin Biopharmaceutical Co., Ltd. He indirectly controls 22.1% of the company via Hunan Xinhexin Biopharmaceutical.
2. Shareholder & Investor Impact and Key Points to Note
- Signal to Shareholders: The controlling shareholder’s move to purchase shares is a strong sign of confidence in the company’s future and long-term value, which can boost market confidence and stabilize the share price.
- Price Sensitive Information: Such share purchases are typically interpreted as a positive signal and could support or lift the share price in the short term.
- Risks: The company warned that the plan may be delayed or fail due to policy changes, market conditions, or other unforeseen risks. Investors should monitor related disclosures.
- Shareholding Structure: The purchase will not change the controlling shareholder or actual controller; shareholding structure remains stable.
- Disclosure: Ongoing updates on the plan’s progress will be provided.
3. Details
- Current Holdings: Prior to the purchase, neither Mr. Liu nor Hunan Chuntou held shares directly, but control 22.1% via Hunan Xinhexin Biopharmaceutical.
- Purchase Amount: RMB 30–60 million, no specific share quantity or proportion set.
- Method: Via centralized bidding on the SSE.
- Compliance: The plan strictly adheres to relevant securities laws and exchange rules.
4. Investor Advisory
This share purchase signals management’s positive outlook and may have a favorable short-term impact on the share price. Investors should watch for further updates and remain aware of policy or market risks.
Disclaimer: This is for news and informational purposes only and does not constitute investment advice. Please make independent investment decisions. Investing is risky; proceed with caution.
